Entecavir
Back to searchMolecule Structure
Scientific Name
Entecavir
Description of the Drug
Entecavir is a nucleoside analogue used in the treatment of chronic hepatitis B for patients with active viral replication, histological evidence of active disease, or persistent elevations in liver transaminases.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00442
http://www.drugbank.ca/drugs/DB00442
Brand Name(s)
Baraclude, Entecavir
Company Owner(s)
Pharmadax Inc, Cipla Ltd, Sunshine Lake Pharma Co Ltd, Bristol Myers Squibb, Rising Pharma Holding Inc, Brightgene Bio-Medical Technology Co Ltd, Casi Pharmaceuticals Inc, Yung Shin Pharmaceutical Industrial Co Ltd, Accord Healthcare Inc, Yaopharma Co Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA polymerase/reverse transcriptase | SINGLE PROTEIN | INHIBITOR | CHEMBL2362994 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL28648 | ||
| PharmGKB | PA164784025 | ||
| Human Metabolome Database | HMDB0014585 | ||
| DrugBank | DB00442 | ||
| PubChem: Thomson Pharma | 14848612 | 14824340 | |
| PubChem | 135398508 | ||
| LINCS | LSM-5258 | ||
| Nikkaji | J846.317D | ||
| BindingDB | 50248008 | ||
| EPA CompTox Dashboard | DTXSID4046446 | ||
| DrugCentral | 1019 | ||
| ChemicalBook | CB83050248 | ||
| rxnorm | ENTECAVIR | ENTECAVIR ANHYDROUS | BARACLUDE |
| PubChem: Drugs of the Future | 12014687 | ||
| ChEBI | 473990 | ||
| ZINC | ZINC000003802690 |
